Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 | O60706 | 12/20 | 0.36 |
| ▸ | KCNJ11 | Q14654 | 12/20 | 0.36 |
| ▸ | ABCC8 | Q09428 | 11/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 11/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31474102 | 0.84 | KDM1A (0.38) | SLC6A4SLC6A3SLC6A2OPRD1 | |
| SCHEMBL14625259 | 0.81 | SLC6A3 (0.47) | SLC6A4SLC6A3SLC6A2OPRD1 | |
| SCHEMBL4745351 | 0.78 | HDAC3 (0.40) | SLC6A4SLC6A3SLC6A2IDO1 | |
| SCHEMBL17478868 | 0.76 | SLC6A4 (0.36) | ABCC9KCNJ11ABCC8KCNJ8SLC6A4 | |
| SCHEMBL8226487 | 0.76 | DRD2 (0.36) | ABCC9KCNJ11ABCC8KCNJ8SLC6A4 | |
| SCHEMBL14625193 | 0.76 | SLC6A3 (0.51) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL1905906 | 0.76 | SLC6A4 (0.36) | SLC6A4SLC6A3SLC6A2OPRD1 | |
| SCHEMBL29041120 | 0.76 | OPRM1 (0.38) | ABCC9KCNJ11ABCC8KCNJ8SLC6A4 | |
| SCHEMBL5276807 | 0.76 | SMN1; SMN2 (0.43) | ABCC9KCNJ11ABCC8KCNJ8SLC6A3 | |
| SCHEMBL12898001 | 0.73 | AKR1B10 (0.45) | SLC6A4SLC6A3SLC6A2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117120090-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2023-11-24 | — | — | CN | disclosed |
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-30 | — | — | US | disclosed |
| WO-2022174253-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230096641-A1 | HPK1 ANTAGONISTS AND USES THEREOF | PDXK, HIPK1, PCK1 | ABCC9 2650/4885KCNJ11 1406/4885ABCC8 2189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.